TY - JOUR
T1 - Therapeutic response of patients with adult Still's disease to biologic agents
T2 - Multicenter results in Japan
AU - Suematsu, Rie
AU - Ohta, Akihide
AU - Matsuura, Emi
AU - Takahashi, Hiroki
AU - Fujii, Takao
AU - Horiuchi, Takahiko
AU - Minota, Seiji
AU - Ishigatsubo, Yoshiaki
AU - Ota, Toshiyuki
AU - Takei, Shuji
AU - Soejima, Sachiko
AU - Inoue, Hisako
AU - Koarada, Syuichi
AU - Tada, Yoshifumi
AU - Nagasawa, Kohei
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/9
Y1 - 2012/9
N2 - Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.
AB - Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.
UR - http://www.scopus.com/inward/record.url?scp=84870371697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870371697&partnerID=8YFLogxK
U2 - 10.1007/s10165-011-0569-6
DO - 10.1007/s10165-011-0569-6
M3 - Article
C2 - 22160845
AN - SCOPUS:84870371697
SN - 1439-7595
VL - 22
SP - 712
EP - 719
JO - Modern Rheumatology
JF - Modern Rheumatology
IS - 5
ER -